Omics-Based Clinical Trials Market Report 2026

The omics-based clinical trials market size has grown strongly in recent years. It will grow from $31.71 billion in 2025 to $34.49 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to increasing complexity of clinical trial designs, growth in genomic and proteomic research, rising demand for personalized therapies, expansion of clinical research infrastructure, increasing collaboration between pharma and academic institutions.

The omics-based clinical trials market size is expected to see strong growth in the next few years. It will grow to $47.78 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing adoption of precision medicine approaches, rising investments in data-driven clinical trials, expansion of ai-enabled patient recruitment, growing regulatory acceptance of omics-based endpoints, increasing demand for efficient trial outcomes. Major trends in the forecast period include increasing adoption of biomarker-driven trial designs, rising use of multi-omics patient stratification, growing integration of real-world evidence analytics, expansion of precision oncology clinical trials, enhanced focus on data-centric trial optimization.

The rising demand for personalized medicine is expected to drive the growth of the omics-based clinical trials market in the coming years. Personalized medicine is a healthcare approach that tailors disease prevention, diagnosis, and treatment to the individual characteristics of each patient. This demand is increasing due to advances in genomic technologies, which enable faster and more cost-effective analysis of individual genetic profiles to guide targeted treatments. Omics-based clinical trials support personalized medicine by identifying individual genetic, proteomic, and metabolic profiles, allowing for more precise and effective treatment strategies tailored to each patient. For example, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit research organization, the US Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, up from six approvals in 2022, including seven oncology therapies and three treatments for other conditions. Consequently, the growing demand for personalized medicine is contributing to the expansion of the omics-based clinical trials market.

Key companies in the omics-based clinical trials market are focusing on innovative technologies, such as HiFi sequencing, to improve the accuracy, speed, and depth of multi-omics data analysis, thereby enhancing trial outcomes and personalized treatment strategies. HiFi sequencing is a next-generation sequencing (NGS) technology that generates long, highly accurate reads using circular consensus sequencing (CCS), enabling precise analysis of genomes, transcriptomes, and epigenomes. For instance, in October 2024, Pacific Biosciences of California Inc., a US-based biotechnology company, in collaboration with the Agency for Science, Technology, and Research (A*STAR) in Singapore and Macrogen Inc., a South Korea-based biotechnology company, launched a state-of-the-art laboratory in Singapore to accelerate genomics innovation with advanced long-read sequencing technology. The facility enables high-precision genomic studies, supporting applications such as whole genome sequencing, transcriptomics, epigenetics, and metagenomics. It also promotes collaboration among global scientists and local institutions, accelerating discoveries in personalized medicine, rare disease diagnostics, and precision oncology, while providing training programs and shared access to high-throughput sequencing infrastructure to foster innovation and capacity-building in the Asia-Pacific region.

In June 2025, Bruker Corporation, a US-based manufacturer of scientific instruments and diagnostic tests, acquired Biocrates Life Sciences AG for an undisclosed amount. Through this acquisition, Bruker aims to strengthen its multiomics solutions by integrating Biocrates’ mass spectrometry-based metabolomics technologies, delivering standardized, reproducible, and comprehensive quantitative workflows for life sciences and clinical research. Biocrates Life Sciences AG is an Austria-based biotechnology company that provides omics-based clinical trial solutions.

Major companies operating in the omics-based clinical trials market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GlaxoSmithKline Plc, Eli Lilly and Company, Novo Nordisk A/S, BioNTech SE, IQVIA Inc., Laboratory Corporation of America Holdings, ICON Public Limited Company, SGS Société Générale de Surveillance SA, Eurofins Scientific SE, Syneos Health Inc., Illumina Inc., Charles River Laboratories International Inc., Parexel International Corporation, Bruker Corporation, Fulgent Genetics Inc., Signios Biosciences, BioAro Inc.

North America was the largest region in the omics-based clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omics-based clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the omics-based clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the omics-based clinical trials market by increasing costs of imported sequencing platforms, laboratory reagents, analytical software, and specialized trial equipment used across genomics and proteomics studies. Pharmaceutical companies and CROs in North America and Europe are most affected due to reliance on imported research tools, while Asia-Pacific faces higher operational costs for trial execution. These tariffs are extending trial timelines and increasing study budgets. However, they are also encouraging localized laboratory services, domestic data analytics development, and regional clinical research collaborations.

The omics-based clinical trials market research report is one of a series of new reports that provides omics-based clinical trials market statistics, including omics-based clinical trials industry global market size, regional shares, competitors with a omics-based clinical trials market share, detailed omics-based clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the omics-based clinical trials industry. This omics-based clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Omics-based clinical trials are clinical studies that utilize omics technologies - such as genomics, proteomics, transcriptomics, metabolomics, and epigenomics - to investigate disease mechanisms, identify biomarkers, predict therapeutic responses, and personalize medical treatments. These trials leverage high-throughput molecular data to guide patient selection, stratification, and treatment optimization, with the ultimate goal of improving outcomes and minimizing adverse effects through precision medicine approaches.

The primary types of omics-based clinical trials include genomics, proteomics, metabolomics, and transcriptomics. Genomics focuses on analyzing an organism’s complete DNA sequence to understand gene structure, function, and their role in health and disease. These trials progress through phases I, II, III, and IV and typically employ study designs such as interventional studies, observational studies, and expanded access studies. Omics-based trials are applied across multiple therapeutic areas, including oncology, cardiovascular diseases, neurology, infectious diseases, and metabolic disorders. They serve a range of end users, including pharmaceutical and biotechnology companies, academic and research institutions, contract research organizations (CROs), and hospitals and diagnostic laboratories.

The omics-based clinical trials market consists of revenues earned by entities by providing services such as genomics analysis, transcriptomics profiling, proteomics studies, and metabolomics assessments. The market value includes the value of related goods sold by the service provider or included within the service offering. The omics-based clinical trials market also includes sales of next-generation sequencing (NGS) platforms, mass spectrometry instruments, microarrays, bioinformatics software, reagents, and kits. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.